Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 27, 2008
Grant Date -
Jan 17, 2008
app pub date -
Jul 14, 2006
filing date -
Jul 14, 2006
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5'-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic keratosis. The Fosfluridine Tidoxil can be systemically administered alone or in combination with topical treatment agents.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully